ferrets report from bourse

  1. blt
    164 Posts.
    ANZ (ANZ) down 14c to $18.16: Plumbed $17.95 when the shares
    were reinstated this morning. Market's first chance to respond to the
    bank's 1 per cent rise in net profit to $2.35 billion for the year.
    Also, ANZ will make a $3.6 billion 2-for-11 issue at $13 a share to help
    fund the acquisition of National Bank of New Zealand for $4.9 billion.

    ARISTOCRAT (ALL) up 18c to $2.50: Rose 10c yesterday as rumours
    continue to circulate that the poker machine maker will soon appoint a
    new chief executive, namely Unitab chief executive Dick McIlwain.
    Brokers said the share price surge may also be due to interest from
    Malaysian casino operator Genting Group.

    RED METAL (RDM) down 3c to 30c: Stags taking profits after a
    strong sharemarket debut yesterday, which saw the 20c shares touch 38c.
    Targeting giant copper and copper/gold deposits in Australia, the
    company is in a strategic alliance with copper leader Phelps Dodge.

    UNITRACT (UNI) up 19c to $2.29: The company today said it had
    lodged patent applications for an interchangeable needle mount, which is
    aimed at making its syringes more suitable for the clinical injection
    requirements of healthcare facilities.

    POLARTECHNICS (PLT) up 2c to 85c: Follows media reports the
    company has launched its cancer-screening devices in Europe and is
    confident of sales in the US within a year.

    SEVEN NETWORK (SEV) up 8c to $6.13: Climbed 26c yesterday.
    Continuing to attract buyers after Friday's announcement of a $275
    million off-market share buyback.

    B DIGITAL (BBB) up 0.5c to 16.5c: Agreed to buy Digiplus
    Investments for $20.4 million in cash and the issue of 333.3 million B
    Digital shares, representing 57 per cent of issued capital. The
    acquisition will lift B Digital's customer base above 430,000.

    EPITAN (EPT) down 1c to 84c: Was up 6c in an erratic morning's
    business. Rose 7c yesterday. The company today reported outstanding
    results in its Phase IIb "sunburn injury" clinical trial represented "a
    massive step forward" in the commercialisation of the Melanotan drug.
    ENDS
    !END
 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.